Medically reviewed by Archana Sharma, DO The prostate health index (PHI) is a blood test that more accurately assesses the risk of prostate cancer than a traditional PSA test. The PHI combines three ...

In the US, prostate cancer is the second leading cause of cancer death in men – but experts can’t agree about testing ...

Changes in screening recommendations over a decade ago may have inadvertently resulted in later diagnosis of the most common ...

Confirmatory testing in low-risk prostate cancer increased from 2017 to 2022, but a payment incentive program did not ...

Dr. David A. Taub discussed why Prostate Cancer Awareness Month marks a time to highlight early detection and evolving ...

For doctors and patients, the Holy Grail of medicine would be a simple blood or saliva test to detect all types of cancer ...

The media frenzy surrounding former President Joe Biden’s metastatic prostate cancer diagnosis last May didn’t faze one ...

A urine-based biomarker panel detected prostate cancer in 91% of specimens with a diagnostic accuracy of 78.6% to 85.7%, according to a study published Sept. 2 in eBioMedicine.  Led by a team from ...

New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer ...

The Decipher Prostate test is a whole-transcriptome-derived, 22-gene signature that clinicians use to help assess the likelihood of a prostate tumor progressing to metastatic disease.

Following hormone therapy, patients with prostate cancer may perceive an increase in cognitive issues, despite tests showing no objective decline, a recent meta-analysis found.